Exact Sciences Corporation (NASDAQ:EXAS) SVP D Scott Coward sold 29,115 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $47.16, for a total value of $1,373,063.40. Following the sale, the senior vice president now owns 64,991 shares of the company’s stock, valued at approximately $3,064,975.56. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Shares of Exact Sciences Corporation (NASDAQ EXAS) opened at 47.99 on Thursday. The stock has a 50 day moving average price of $42.81 and a 200-day moving average price of $34.86. The stock’s market cap is $5.72 billion. Exact Sciences Corporation has a 12-month low of $13.05 and a 12-month high of $50.65.

Exact Sciences Corporation (NASDAQ:EXAS) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.10. The company had revenue of $57.65 million for the quarter, compared to analysts’ expectations of $47.73 million. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. Equities analysts anticipate that Exact Sciences Corporation will post ($1.18) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “D Scott Coward Sells 29,115 Shares of Exact Sciences Corporation (EXAS) Stock” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/05/d-scott-coward-sells-29115-shares-of-exact-sciences-corporation-exas-stock.html.

EXAS has been the subject of a number of recent research reports. Vetr downgraded Exact Sciences Corporation from a “hold” rating to a “sell” rating and set a $34.70 price objective for the company. in a research report on Wednesday, July 12th. Leerink Swann set a $45.00 price objective on Exact Sciences Corporation and gave the company a “buy” rating in a research report on Thursday, August 24th. Roth Capital increased their price objective on Exact Sciences Corporation from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Wednesday, July 26th. Craig Hallum increased their price objective on Exact Sciences Corporation from $35.00 to $41.00 in a research report on Friday, July 7th. Finally, BidaskClub downgraded Exact Sciences Corporation from a “buy” rating to a “hold” rating in a research report on Friday, June 16th. Five research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $43.11.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Fortaleza Asset Management Inc. bought a new position in shares of Exact Sciences Corporation during the second quarter worth $106,000. Krilogy Financial LLC boosted its position in shares of Exact Sciences Corporation by 1,460.0% during the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after purchasing an additional 3,650 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of Exact Sciences Corporation by 17.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after purchasing an additional 600 shares in the last quarter. Financial Architects Inc boosted its position in shares of Exact Sciences Corporation by 90.0% during the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock worth $152,000 after purchasing an additional 2,035 shares in the last quarter. Finally, Johnson Financial Group Inc. boosted its position in shares of Exact Sciences Corporation by 25.9% during the second quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock worth $172,000 after purchasing an additional 1,000 shares in the last quarter. 85.23% of the stock is currently owned by institutional investors.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Stock Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related stocks with our FREE daily email newsletter.